tretinoin and Lichen-Sclerosus-et-Atrophicus

To study the use of topical tretinoin for treating vulvar lichen sclerosus.. An open, uncontrolled clinical study on 22 patients affected by histologically confirmed vulvar lichen sclerosus. Topical 0.025% tretinoin was applied once a day, five days a week, for one year. Clinical and histologic parameters were evaluated before and after therapy, and statistical analysis was performed.. Symptoms, gross appearance and histopathologic features improved in a highly significant manner (P < .001). Cutaneous side effects were observed but rapidly disappeared, and no patient left the study for this reason. Maintenance of results was observed at the 4-13-month follow-up visits.. Topical tretinoin seems feasible for use in the topical treatment of vulvar lichen sclerosus.

Topics: Administration, Topical; Adult; Aged; Biopsy; Dose-Response Relationship, Drug; Female; Humans; Keratolytic Agents; Lichen Sclerosus et Atrophicus; Middle Aged; Skin Diseases; Time Factors; Tretinoin; Vulva; Vulvar Diseases

Topics: Adult; Ainhum; Anti-Inflammatory Agents; Clobetasol; Constriction, Pathologic; Drug Therapy, Combination; Humans; Lichen Sclerosus et Atrophicus; Male; Penile Diseases; Tretinoin